Researchers at the Buck Institute conducted a clinical trial testing therapeutic plasma exchange (TPE) combined with intravenous immunoglobulin (IVIG) as a strategy to reverse biological aging. Using multi-omics analysis — measuring molecular markers across the genome, proteome, and epigenome — they found participants receiving TPE plus IVIG experienced an average reduction in biological age of 2.6 years. This approach is grounded in the concept that aging factors circulating in blood can be diluted or replaced to restore a more youthful molecular profile. The results were published in the journal Aging Cell. This trial is among the first to demonstrate measurable biological age reversal in humans using a blood-based intervention, adding meaningful clinical evidence to a field that has largely relied on animal studies.
